INTRODUCTION
Populations are rapidly aging worldwide. This is particularly true in Japan, where there is an increased need to address problems associated with the aging population [1, 2] . One consequence of population aging is an increase in the number of elderly patients with diabetes mellitus [glycated hemoglobin A1c (HbA1c) C 6.5%] [3] . A Japanese nationwide survey reported an increase in the prevalence of diabetes mellitus with advancing age, and diabetes mellitus was suspected in approximately 23% of men and 12% of women aged C60 years [3] . These patients often have atherosclerotic complications [4, 5] , and diabetes prevention and management are strongly desired to promote health and reduce the impact on healthcare expenditure. Diabetes treatment guidelines that recommend intensive multifactorial interventions to prevent macro-and microcomplications have been established for young and middle-aged patients with diabetes [5] . However, treatment strategies for elderly patients with diabetes are not well established, and treatment goals for glycemic control are controversial because of insufficient accumulated clinical evidence and difficulties associated with intensive therapy in elderly patients [4] [5] [6] . Of particular concern, intensive treatment in elderly patients with diabetes may increase risk of death [7] , falls [8] , and cognitive function decline [9] due to hypoglycemic events. Therefore, glycemic control targets should depend on individual patient characteristics, for example, the newest position statement recommends lower glycemic control targets (HbA1c\6.5-7.0%) for healthy elderly patients, while an HbA1c\7.0-8.0% may be acceptable if lower targets cannot be achieved [6] .
Regardless of these concerns, comprehensive management to prevent atherosclerotic complications requires the achievement of adequate glycemic control in elderly as well as non-elderly patients with diabetes [4, 5] .
Unfortunately, only a few studies have evaluated the safety and efficacy of comprehensive management in elderly patients [10] . The current study was an agespecific evaluation of the effectiveness and safety of newly initiated insulin therapy over a 1-year period in elderly (C65 years) and nonelderly (B64 years) Japanese patients with uncontrolled diabetes, incorporating comprehensive management with SMBG.
MATERIALS AND METHODS

Patients
The present study was a retrospective cohort study conducted at a specialist medical clinic 
RESULTS
Patients
During the study period, 132 patients with type 2 diabetes began insulin therapy at the medical clinic. Thirty-two of these patients were excluded from the current study based on exclusion criteria (4), lack of data (13), or were lost to follow-up (15) . The remaining 100
patients were enrolled in the study. Baseline characteristics of these participants are shown in Table 1 .
Of the 100 participants, 33 (33.0%) were elderly (C65 years) and 67 (67.0%) were non- respectively. Antihypertensive drug use was significantly more frequent (57.6% vs 26.9%, P\0.01) and diabetic neuropathy was more common (75.8% vs 46.3%, P\0.01) among elderly compared to non-elderly patient.
At baseline, elderly patients were prescribed sulfonylureas and biguanides to treat diabetes more frequently than non-elderly patients (Table 1) . After initiation of insulin therapy, non-elderly patients were more likely to be treated with ultra-rapid insulin (62.7% vs 15.2%, P\0.01), while elderly patients were more likely to be treated with long-acting insulin (20.9% vs 60.6%, P\0.01). No severe hypoglycemic complications were observed in either group during the study period; insulin therapy was stopped in 3 elderly (9.1%) and 10 non-elderly (14.9%) patients because of improvements in their glycemic control. 
Glycemic Control
Changes from baseline in glycemic control, lipid profiles, body weight, and insulin dosage are shown in Tables 2 and 3 . In the non-elderly patient group, HbA1c levels were significantly improved at 3 (P\0.01), 6 (P\0.01) and 12 months (P\0.01) after initiation of insulin therapy, and reached 7.3% (range 6.0-12.0) at 12 months [-3.8% (-11.4, 0.9), P\0.01]. 
\0.01
Change in HbA1c (%) The Wilcoxon signed-rank test was used for paired analyses to compare to baseline data HbA1c glycated hemoglobin vs 76.9%, P = 0.04) ( Table 4) .
DISCUSSION
This retrospective cohort survey conducted at one medical clinic in Japan revealed the effectiveness of intensive insulin therapy for elderly Japanese patients (C65 years) with uncontrolled diabetes mellitus, demonstrating an improvement in glycemic control 1 year after initiation of insulin therapy that was comparable to that observed in non-elderly patients (\65 years). In addition, severe hypoglycemic events were avoided in both age groups by comprehensive management using SMBG. This study suggests the potential for safely improving poor glycemic control among elderly patients as well as non-elderly patients by initiating insulin therapy. However, 37.8% of non-elderly and 19.2% of elderly still experienced poor glycemic control 8.07 .0~7.9
6.0~6. [14, 15] . A 6-year interventional observational study conducted in Japan reported an association between high HbA1c levels and the development of retinopathy, and that intensive control of diabetes mellitus led to favorable outcomes [14] . A study in Nagoya, Japan, found no increase in mortality among well-controlled elderly patients with diabetes compared to the general population after matching for age and sex [15] . Thus, better management of diabetes might prevent and/or delay diabetic complications or improve mortality, despite minimal accumulated evidence in the elderly.
In general practice, improving uncontrolled diabetes in elderly patients is sometimes more difficult than in non-elderly patients because of age-related deterioration in glucose tolerance and a reduction in endogenous insulin secretion, and therefore treatment is likely to require insulin initiation in elderly patients with uncontrolled glycemic control [16] . The Kumamoto study, a randomized controlled trial evaluating intervention with insulin therapy among 110 Japanese patients with uncontrolled type 2 diabetes, revealed the effectiveness of intensive treatment for primary and secondary prevention of diabetic complications, and showed that treatment with multiple insulin injections per day was more beneficial for total medical costs at 10 years of follow-up compared to a Several reports have brought attention to excessively strict glycemic control strategies.
The Diabetes and Aging Study, a large-scale retrospective cohort study of 71,092 patients in the United States with diabetes mellitus, reported that mortality had a U-shaped relationship with HbA1c, with an increased risk of all-cause mortality associated with HbA1c levels less than 6% [19] . In the Health, Aging, and Body Composition Study, a prospective study conducted in the United States, insulin users with HbA1c levels B6.0% had a 4.36-fold higher risk of falls compared to those individuals with HbA1c levels C8.0% [8] .
In addition to the above-mentioned influences on mortality and morbidity, hypoglycemic events can trigger a series of complications [8, 20] . In a large-scale cohort study in the United States, patients with diabetes (mean age, 64.0 years) who experienced hypoglycemic events were 1.79 times more likely to experience an acute cardiovascular events than those who did not experience hypoglycemic events; similar results were also reported for patients aged C65 years compared to those for the entire population (odds ratio = 1.78) [20] . In addition, the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, which was a randomized trial among diabetic patients aged 40-79 years with cardiovascular histories or their risks, showed that the risk of severe hypoglycemia in an intensive glycemic control group (HbA1c goal\6%) was more than threefold higher than in a standard glycemic control group (HbA1c goal 7.0-7.9%); furthermore, the mortality risk was 1.22-fold higher in the intensive compared to the standard glycemic control group [7] . Therefore, avoidance of hypoglycemia is necessary for better glycemic control and to reduce mortality and morbidity. To avoid hypoglycemia in our study, we used SMBG, according to Japanese Diabetes Management Guidelines [21] , which involved regularly checking patient HbA1c levels and SMBG records, and modifying their treatment accordingly. No severe hypoglycemic events were observed in either the elderly or non-elderly groups during the 1-year follow-up period. SMBG may allow patients to evaluate their glucose concentrations and assess their achievement status to target glycemic levels [5, 22] . Therefore, comprehensive management that includes SMBG is a useful strategy for improving awareness and avoiding hypoglycemic events among insulin-treated elderly patients [5, 22] . In addition, the use of long-acting insulin may also avoid the problem of hypoglycemia in elderly patients. The APOLLO study, comparing once-daily basal insulin glargine (long-acting insulin) versus thrice-daily prandial insulin lispro (short- and elderly patient groups. A large-scale study is required to adjust for these differences. Finally, 1 year is a relatively short study period. As a next step, cohort studies with long study periods (more than 5 years) are needed to assess long-term outcomes including glycemic control, onset of cardiovascular complications, mortality, and morbidity.
CONCLUSION
Our results indicate that newly initiated insulin therapy is as effective and safe for treating elderly Japanese patients with uncontrolled diabetes as for treating non-elderly patients.
The study also clarified the utility of comprehensive management and education using SMBG to improve glycemic control and avoid hypoglycemia. The number of elderly patients with diabetes is expected to significantly increase not only in Japan, but worldwide too. Reducing morbidity and mortality requires improved glycemic control supported by adequate intensive management.
ACKNOWLEDGMENTS
We thank the staff of Taneda 
